Terms: = Germ cell tumor AND FCGR2B, FCGR2, 2213, ENSG00000072694, CD32, CD32B, P31994, IGFR2, FCG2 AND Prognosis
6 results:
1. fcgr2b as a prognostic and immune microenvironmental marker for gliomas based on transcriptomic analysis.
Sun Z; Sun X; Yuan Y; Li H; Li X; Yao Z
Medicine (Baltimore); 2023 Sep; 102(37):e35084. PubMed ID: 37713871
[TBL] [Abstract] [Full Text] [Related]
2. An immunosuppressed microenvironment distinguishes lateral ventricle-contacting glioblastomas.
Bartkowiak T; Lima SM; Hayes MJ; Mistry AM; Brockman AA; Sinnaeve J; Leelatian N; Roe CE; Mobley BC; Chotai S; Weaver KD; Thompson RC; Chambless LB; Ihrie RA; Irish JM
JCI Insight; 2023 Jun; 8(12):. PubMed ID: 37192001
[TBL] [Abstract] [Full Text] [Related]
3. Gene expression-based biomarkers designating glioblastomas resistant to multiple treatment strategies.
Menyhárt O; Fekete JT; Győrffy B
Carcinogenesis; 2021 Jun; 42(6):804-813. PubMed ID: 33754151
[TBL] [Abstract] [Full Text] [Related]
4. Bioinformatic profiling identifies an immune-related risk signature for glioblastoma.
Cheng W; Ren X; Zhang C; Cai J; Liu Y; Han S; Wu A
Neurology; 2016 Jun; 86(24):2226-34. PubMed ID: 27225222
[TBL] [Abstract] [Full Text] [Related]
5. The Expression Quantitative Trait Loci in Immune Pathways and their Effect on Cutaneous Melanoma prognosis.
Vogelsang M; Martinez CN; Rendleman J; Bapodra A; Malecek K; Romanchuk A; Kazlow E; Shapiro RL; Berman RS; Krogsgaard M; Osman I; Kirchhoff T
Clin Cancer Res; 2016 Jul; 22(13):3268-80. PubMed ID: 26733611
[TBL] [Abstract] [Full Text] [Related]
6. A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon.
Wang E; Zhao Y; Monaco A; Uccellini L; Kirkwood JM; Spyropoulou-Vlachou M; Panelli MC; Marincola FM; Gogas H
PLoS One; 2012; 7(7):e40805. PubMed ID: 22911710
[TBL] [Abstract] [Full Text] [Related]
